Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide

Lupus

Volumn 16, Issue 9, 2007, Pages 707-712

  Wang, J ^a   Hu, Weixin ^a,b   Xie, H ^a   Zhang, H ^a   Chen, H ^a   Zeng, C ^a   Liu, Z ^a   Li, L ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Cyclophosphamide; Lupus nephritis; Mycophenolate mofetil; Noninflammatory necrotizing vasculopathy; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOUBLE STRANDED DNA ANTIBODY; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; GASTROINTESTINAL SYMPTOM; HEMATURIA; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RENAL NONINFLAMMATORY NECROTIZING VASCULOPATHY; RENOVASCULAR DISEASE; SIDE EFFECT; TREATMENT RESPONSE; URINARY EXCRETION;

ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEMATURIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; VASCULAR DISEASES;

EID: 34948895412     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307081340     Document Type: Article

References (21)

1. Appel GB, Pirani CL, D'Agati. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499-1515.
2. Banfi G, Bertani F, Boen V et al. Renal vascular lesions as a marker of a poor prognosis in patients with LN. Am J Kidney Dis 1991; 18: 240-248.
3. Yao G, Hu WX, Liu ZH et al. The significance of renal vascular lesion in patients with proliferative lupus nephritis. J Nephrol Dialy Transplant 2002; 11: 211-217.
4. Bhathena DB, Sobel BJ, Migdal SD. Noninflammatory renal microangiopathy of systemic lupus erythematosus ('lupus vasculitis'). Am J Nephrol 1981; 1: 144-159.
5. Sung JM, Hsu SC, Chen FF et al. Systemic lupus erythematosus presented as non-inflammatory necrotizing vasculopathy-induced ischemic glomerulopathy and small vessels-related ischemic cardiomyopathy. Lupus 2002; 11: 458-462.
6. Grishman E, Venkataseshan VS. Vascular lesions in LN. Mod Pathol 1988; 1: 235-241.
7. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945-950.
8. Ioannidis JPA, Boki KA, Katsorida EM et al. Remission, relapse and reremission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
9. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559-2568.
10. Cortes-Hernandez J, Ordi-Rios J, Labrador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296.
11. Gaubitz M, Schorat A, Schotte H et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-736.
12. Kingdon EJ, McLean AG, Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606 -611.
13. Hu WX, Liu ZH, Chen HP et al. MMF vs. cyclophosphamide therapy for patients with diffuse proliferative LN. Chin Med J (Engl) 2002; 115: 705-709.
14. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
15. Weening JJ, D'agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
16. Austin HA III, Muenz LR, Joyce KM et al. Diffuse proliferative LN: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
17. Descombes E, Droz D, Drouet L et al. Renal vascular lesions in LN. Medicine (Baltimore) 1997; 76: 355-368.
18. Chien-Te W, Lin-Shien F. Lupus vasculopathy combined with acute renal failure in LN. Pediatr Nephrol 2003; 18: 1304-1307.
19. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
20. Gaubitz M, Schorat A, Schotte H et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-736.
21. Flores-Suarez LF. Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil. Arch Med Res 2006; 37: 68-73.